Abstract |
The effect of the newly synthesized pyridoindole antioxidant SMe1EC2 (1 micromol/l) and drugs activating or inhibiting adenosine receptors was tested under ischemia. Synaptic transmission was recorded extracellularly before and under 6-min ischemia and 20-min reoxygenation in rat hippocampal slices in vitro. In untreated slices, ischemia elicited failure of synaptic transmission and excitability expressed by a population spike decay (t(0.5) = 1.7 +/- 0.1 min) and poor recovery of synaptic transmission at the end of reoxygenation, expressed as percentage of PoS amplitude of that at zero minute of ischemia (9.9 +/- 3.6%). The compound SMe1EC2 increased recovery of PoS amplitude in reoxygenation (31.2 +/- 7.0% of that at the beginning of ischemia) and decreased the number of irreversibly damaged slices in reoxygenation (64%) compared to untreated slices (80%). Co-administration of SMe1EC2 + SCH-58261 (1 micromol/l, A(2A) adenosine receptor antagonist) resulted in delayed synaptic transmission decay during 6-min ischemia (t(0.5) = 2.3 +/- 0.1 min), increased PoS amplitude recovery during reoxygenation (37.7 +/- 12.4% of that at zero minute of ischemia), and in a decreased number of slices with damaged synaptic transmission at the end of reoxygenation (54%), all data compared to untreated controls. Co-administration of pyridoindole with CGS 21680 (1 micromol/l, A(2A) adenosine receptor agonist) or with DPCPX (100 nmol/l, A(1) adenosine receptor antagonist) eliminated the described effect. Further studies are required to elucidate the putative influence of manipulation with adenosine receptors on the neuroprotective effect of SMe1EC2 under ischemia.
|
Authors | Zdenka Gáspárová, Pavol Jariabka, Svorad Stolc |
Journal | Pharmacological reports : PR
(Pharmacol Rep)
2008 May-Jun
Vol. 60
Issue 3
Pg. 353-60
ISSN: 1734-1140 [Print] Switzerland |
PMID | 18622060
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
- Adenosine A1 Receptor Agonists
- Adenosine A1 Receptor Antagonists
- Adenosine A2 Receptor Agonists
- Adenosine A2 Receptor Antagonists
- Antioxidants
- Indoles
- Neuroprotective Agents
- Phenethylamines
- Pyridines
- Pyrimidines
- Receptor, Adenosine A1
- Receptor, Adenosine A2A
- SMe1EC2
- Triazoles
- Xanthines
- 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
- N(6)-cyclopentyladenosine
- 1,3-dipropyl-8-cyclopentylxanthine
- Adenosine
- Oxygen
|
Topics |
- Action Potentials
(drug effects, physiology)
- Adenosine
(analogs & derivatives, pharmacology)
- Adenosine A1 Receptor Agonists
- Adenosine A1 Receptor Antagonists
- Adenosine A2 Receptor Agonists
- Adenosine A2 Receptor Antagonists
- Animals
- Antioxidants
(chemistry, pharmacology)
- Dose-Response Relationship, Drug
- Electrophysiology
- Hippocampus
(drug effects, physiopathology)
- Hypoxia
(physiopathology)
- Hypoxia-Ischemia, Brain
(physiopathology)
- In Vitro Techniques
- Indoles
(chemistry, pharmacology, therapeutic use)
- Male
- Neuroprotective Agents
(chemistry, pharmacology)
- Oxygen
(metabolism)
- Phenethylamines
(pharmacology)
- Pyridines
(chemistry, pharmacology, therapeutic use)
- Pyrimidines
(pharmacology)
- Rats
- Rats, Wistar
- Receptor, Adenosine A1
(physiology)
- Receptor, Adenosine A2A
(physiology)
- Synaptic Transmission
(drug effects, physiology)
- Time Factors
- Triazoles
(pharmacology)
- Xanthines
(pharmacology)
|